Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii
Antimicrobial Agents and Chemotherapy · 06.03.2024 · 68 (3)
DOI: 10.1128/aac.01120-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.03.2024. Verfasst von Magdalena Zalacain und 15 weiteren Autor:innen. Beteiligte Einrichtung: Antabio SAS, Labège, France. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Acinetobacter baumannii. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Contrat Innovation, Region Occitanie.
Abstract (Originalsprache)
ANT3310 is a novel broad-spectrum diazabicyclooctane serine β-lactamase inhibitor being developed in combination with meropenem (MEM) for the treatment of serious infections in hospitalized patients where carbapenem-resistant Gram-negative pathogens are expected. In this study, we evaluated the in vitro antibacterial activity of MEM in the presence of ANT3310 at 8 µg/mL against global clinical isolates that included Acinetobacter baumannii ( n = 905), carbapenem-resistant Enterobacterales (CRE), carrying either oxacillinase (OXA) ( n = 252) or Klebsiella pneumoniae carbapenemase (KPC) ( n = 180) carbapenemases, and Pseudomonas aeruginosa ( n = 502). MEM was poorly active against A. baumannii, as were MEM-vaborbactam, ceftazidime-avibactam, aztreonam-avibactam, cefepime-taniborbactam, cefepime-zidebactam, and imipenem-relebactam (MIC 90 values of ≥32 µg/mL). On the other hand, MEM-ANT3310 displayed an MIC 90 value of 4 µg/mL, similar to that observed with sulbactam-durlobactam, a drug developed to specifically treat A. baumannii infections. ANT3310 (8 µg/mL) additionally restored the activity of MEM against OXA- and KPC-producing CREs decreasing MEM MIC 90 values from >32 µg/mL to 0.25 and 0.5 µg/mL, respectively. The combination of 8 µg/mL of both MEM and ANT3310 prevented growth of 97.5% of A. baumannii and 100% of OXA- and KPC-positive CREs, with ~90% of P. aeruginosa isolates also displaying MEM MICs ≤8 µg/mL. Furthermore, MEM-ANT3310 was efficacious in both thigh and lung murine infection models with OXA-23 A. baumannii . This study demonstrates the potent in vitro activity of the MEM-ANT3310 combination against both carbapenem-resistant A. baumannii and Enterobacterales clinical isolates, a key differentiator to other β-lactam/β-lactamase combinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Antabio SAS, Labège, France.
- IHMA Europe, Monthey/VS, Switzerland.
- Evotec, Macclesfield, United Kingdom.
ORCID-Profile: Magdalena Zalacain
Förderung
- Contrat Innovation, Region Occitanie
Zitieren
APA
Zalacain, M., Achard, P., Llanos, A., Morrissey, I., Hawser, S., Holden, K., Toomey, E., Davies, D., Leiris, S., Sable, C., Ledoux, A., Bousquet, J., Castandet, J., Lozano, C., Everett, M., & Lemonnier, M. (2024). Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 68(3). https://doi.org/10.1128/aac.01120-23
Vancouver
Zalacain M, Achard P, Llanos A, Morrissey I, Hawser S, Holden K, et al. Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 2024;68(3). doi:10.1128/aac.01120-23
BibTeX
@article{Zalacain2024,
author = {Zalacain, Magdalena and Achard, Pauline and Llanos, Agustina and Morrissey, Ian and Hawser, Stephen and Holden, Kirsty and Toomey, Eleanor and Davies, David and Leiris, Simon and Sable, Carole and Ledoux, Adeline and Bousquet, Justine and Castandet, Jérôme and Lozano, Clarisse and Everett, Martin and Lemonnier, Marc},
title = {Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {3},
doi = {10.1128/aac.01120-23}
}
EUVIMED